Listen up, folks, we’ve got something very important to talk about – it’s about Systemic lupus erythematosus (SLE), a really tough disease, believe me. And you know what? It’s hitting some people harder than others. We’re talking about African Americans, Mestizos, Asians – they’re dealing with this at a much higher level than Europeans. It’s true, it’s true.

So, we’ve got these brilliant people, the best, and they’re looking into why this is happening. They’ve taken a huge group, 1,139 patients, and they’ve done this incredible thing with the Affymetrix LAT1 World array – very high-tech, very impressive. They’re checking out the ancestry, both the big picture and the nitty-gritty details, to see if it’s got something to do with the disease, especially the really bad stuff like lupus nephritis, when symptoms start, and those nasty autoantibodies.

Now, they’ve crunched the numbers, and guess what? The differences in ancestry, they’re not really showing the big effects we thought they might. We’re talking small, very small effect sizes – not even hitting the mark for being statistically significant. That’s right, whether we’re looking at the global view or zooming in locally in the MHC region, it’s not the major player for these SLE issues in our mixed population.

So, what does this mean? It means that the genetic ancestry in this particular area, the MHC region, it’s not the big bad wolf of SLE manifestations, not by a long shot. And that’s something, that’s really something. This is big news, and it’s got copyright protection, because it’s that important. All rights reserved, folks.